GlaxoSmithKline PLC Director/PDMR Shareholding (5120Q)
19 Febrero 2019 - 7:41AM
UK Regulatory
TIDMGSK
RNS Number : 5120Q
GlaxoSmithKline PLC
19 February 2019
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. Details of PDMR/person closely associated with them
('PCA')
===================================================================================
a) Name Ms E Walmsley
=== =============================== ==================================================
b) Position/status Chief Executive Officer
=== =============================== ==================================================
c) Initial notification/ Initial Notification
amendment
=== =============================== ==================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ===================================================================================
a) Name GlaxoSmithKline plc
=== =============================== ==================================================
b) LEI 5493000HZTVUYLO1D793
=== =============================== ==================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ===================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
=== =============================== ==================================================
b) Nature of the The exercise of nil-cost options over
transaction Ordinary Shares granted on 11 February
2016 under the Company's 2009 Deferred
Annual Bonus Plan - Deferred Bonus a+++++nd
Matching Awards.
=== =============================== ==================================================
c) Price(s) and volume(s) Price(s) Volume(s)
=== =============================== ================ ============================
GBP0.0000 32,596 (Deferred)
=== =============================== ================ ============================
GBP0.0000 19,234 (Matching)
================ ============================
d) Aggregated information
===
Aggregated volume 51,830
Price GBP0.0000
=== =============================== ==================================================
e) Date of the transaction 2019-02-18
=== =============================== ==================================================
f) Place of the transaction n/a
=============================== ==================================================
1. Details of PDMR/person closely associated with them
('PCA')
=====================================================================================
a) Name Ms E Walmsley
=== =============================== ====================================================
b) Position/status Chief Executive Officer
=== =============================== ====================================================
c) Initial notification/ Initial Notification
amendment
=== =============================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =====================================================================================
a) Name GlaxoSmithKline plc
=== =============================== ====================================================
b) LEI 5493000HZTVUYLO1D793
=== =============================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =====================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
=== =============================== ====================================================
b) Nature of the The sale of Ordinary Shares to meet tax
transaction liabilities on nil-cost options over Ordinary
Shares exercised on 18 February 2019 under
the Company's Deferred Annual Bonus Plan
- Deferred Bonus and Matching Awards.
=== =============================== ====================================================
c) Price(s) and volume(s) Price(s) Volume(s)
=== =============================== ================= =============================
GBP15.756 15,345 (Deferred)
=== =============================== ================= =============================
GBP15.756 9,053 (Matching)
================= =============================
d) Aggregated information
===
Aggregated volume 24,398
Price GBP15.756
=== =============================== ====================================================
e) Date of the transaction 2019-02-18
=== =============================== ====================================================
f) Place of the transaction London Stock Exchange (XLON)
=============================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
===================================================================================
a) Name Mr R Connor
=== =============================== ==================================================
b) Position/status President, Global Vaccines
=== =============================== ==================================================
c) Initial notification/ Initial Notification
amendment
=== =============================== ==================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ===================================================================================
a) Name GlaxoSmithKline plc
=== =============================== ==================================================
b) LEI 5493000HZTVUYLO1D793
=== =============================== ==================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ===================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
=== =============================== ==================================================
b) Nature of the The exercise of nil-cost options over
transaction Ordinary Shares granted on 11 February
2016 under the Company's 2009 Deferred
Annual Bonus Plan - Deferred Bonus and
Matching Awards.
=== =============================== ==================================================
c) Price(s) and volume(s) Price(s) Volume(s)
=== =============================== ================ ============================
GBP0.0000 11,073 (Deferred)
=== =============================== ================ ============================
GBP0.0000 6,534 (Matching)
================ ============================
d) Aggregated information
===
Aggregated volume 17,607
Price GBP0.0000
=== =============================== ==================================================
e) Date of the transaction 2019-02-18
=== =============================== ==================================================
f) Place of the transaction n/a
=============================== ==================================================
1. Details of PDMR/person closely associated with them
('PCA')
====================================================================================
a) Name Mr R Connor
=== ================================ ==================================================
b) Position/status President, Global Vaccines
=== ================================ ==================================================
c) Initial notification/ Initial Notification
amendment
=== ================================ ==================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ====================================================================================
a) Name GlaxoSmithKline plc
=== ================================ ==================================================
b) LEI 5493000HZTVUYLO1D793
=== ================================ ==================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ====================================================================================
a) Description of the Ordinary shares of 25 pence each ('Ordinary
financial instrument Shares')
ISIN: GB0009252882
=== ================================ ==================================================
b) Nature of the transaction The sale of Ordinary Shares to meet
tax liabilities on nil-cost options
over Ordinary Shares exercised on 18
February 2019 under the Company's Deferred
Annual Bonus Plan - Deferred Bonus and
Matching Awards.
=== ================================ ==================================================
c) Price(s) and volume(s) Price(s) Volume(s)
=== ================================ ================== ==========================
GBP15.756 5,218 (Deferred)
=== ================================ ================== ==========================
GBP15.756 3,079 (Matching)
================== ==========================
d) Aggregated information
===
Aggregated volume 8,297
Price GBP15.756
=== ================================ ==================================================
e) Date of the transaction 2019-02-18
=== ================================ ==================================================
f) Place of the transaction London Stock Exchange (XLON)
================================ ==================================================
1. Details of PDMR/person closely associated with them
('PCA')
===================================================================================
a) Name Mr S Dingemans
=== =============================== ==================================================
b) Position/status Chief Financial Officer
=== =============================== ==================================================
c) Initial notification/ Initial Notification
amendment
=== =============================== ==================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ===================================================================================
a) Name GlaxoSmithKline plc
=== =============================== ==================================================
b) LEI 5493000HZTVUYLO1D793
=== =============================== ==================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ===================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
=== =============================== ==================================================
b) Nature of the The exercise of nil-cost options over
transaction Ordinary Shares granted on 11 February
2016 under the Company's 2009 Deferred
Annual Bonus Plan - Deferred Bonus and
Matching Awards.
=== =============================== ==================================================
c) Price(s) and volume(s) Price(s) Volume(s)
=== =============================== ================ ============================
GBP0.0000 43,044 (Deferred)
=== =============================== ================ ============================
GBP0.0000 25,398 (Matching)
================ ============================
d) Aggregated information
===
Aggregated volume 68,442
Price GBP0.0000
=== =============================== ==================================================
e) Date of the transaction 2019-02-18
=== =============================== ==================================================
f) Place of the transaction n/a
=============================== ==================================================
1. Details of PDMR/person closely associated with them
('PCA')
====================================================================================
a) Name Mr S Dingemans
=== ================================ ==================================================
b) Position/status Chief Financial Officer
=== ================================ ==================================================
c) Initial notification/ Initial Notification
amendment
=== ================================ ==================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ====================================================================================
a) Name GlaxoSmithKline plc
=== ================================ ==================================================
b) LEI 5493000HZTVUYLO1D793
=== ================================ ==================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ====================================================================================
a) Description of the Ordinary shares of 25 pence each ('Ordinary
financial instrument Shares')
ISIN: GB0009252882
=== ================================ ==================================================
b) Nature of the transaction The sale of Ordinary Shares to meet
tax liabilities on nil-cost options
over Ordinary Shares exercised on 18
February 2019 under the Company's Deferred
Annual Bonus Plan - Deferred Bonus
and Matching Awards.
=== ================================ ==================================================
c) Price(s) and volume(s) Price(s) Volume(s)
=== ================================ ================ ============================
GBP15.716 20,263 (Deferred)
=== ================================ ================ ============================
GBP15.716 11,955 (Matching)
================ ============================
d) Aggregated information
===
Aggregated volume 32,218
Price GBP15.716
=== ================================ ==================================================
e) Date of the transaction 2019-02-18
=== ================================ ==================================================
f) Place of the transaction London Stock Exchange (XLON)
================================ ==================================================
1. Details of PDMR/person closely associated with them
('PCA')
====================================================================================
a) Name Mr P Thomson
=== ================================ ==================================================
b) Position/status President, Global Affairs
=== ================================ ==================================================
c) Initial notification/ Initial Notification
amendment
=== ================================ ==================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ====================================================================================
a) Name GlaxoSmithKline plc
=== ================================ ==================================================
b) LEI 5493000HZTVUYLO1D793
=== ================================ ==================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ====================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
=== ================================ ==================================================
b) Nature of the The exercise of nil-cost options over
transaction Ordinary Shares granted on 11 February
2016 under the Company's 2009 Deferred
Annual Bonus Plan - Deferred Bonus and
Matching Awards.
=== ================================ ==================================================
c) Price(s) and volume(s) Price(s) Volume(s)
=== ================================ ================ ============================
GBP0.0000 9,064 (Deferred)
=== ================================ ================ ============================
GBP0.0000 5,349 (Matching)
================ ============================
d) Aggregated information
===
Aggregated volume 14,413
Price GBP0.0000
=== ================================ ==================================================
e) Date of the transaction 2019-02-18
=== ================================ ==================================================
f) Place of the transaction n/a
================================ ==================================================
1. Details of PDMR/person closely associated with them
('PCA')
====================================================================================
a) Name Mr P Thomson
=== ================================ ==================================================
b) Position/status President, Global Affairs
=== ================================ ==================================================
c) Initial notification/ Initial Notification
amendment
=== ================================ ==================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ====================================================================================
a) Name GlaxoSmithKline plc
=== ================================ ==================================================
b) LEI 5493000HZTVUYLO1D793
=== ================================ ==================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ====================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial instrument Shares')
ISIN: GB0009252882
=== ================================ ==================================================
b) Nature of the transaction The sale of Ordinary Shares to meet tax
liabilities on nil-cost options over
Ordinary Shares exercised on 18 February
2019 under the Company's Deferred Annual
Bonus Plan - Deferred Bonus and Matching
Awards.
=== ================================ ==================================================
c) Price(s) and volume(s) Price(s) Volume(s)
=== ================================ ================== ==========================
GBP15.7215 4,271 (Deferred)
=== ================================ ================== ==========================
GBP15.7215 2,521 (Matching)
================== ==========================
d) Aggregated information
===
Aggregated volume 6,792
Price GBP15.7215
=== ================================ ==================================================
e) Date of the transaction 2019-02-18
=== ================================ ==================================================
f) Place of the transaction London Stock Exchange (XLON)
================================ ==================================================
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHXKLFFKLFXBBD
(END) Dow Jones Newswires
February 19, 2019 08:41 ET (13:41 GMT)
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
